Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of North Carolina |
---|---|
Information provided by: | The University of North Carolina, Chapel Hill |
ClinicalTrials.gov Identifier: | NCT00609531 |
The purpose of this study is to use functional magnetic resonance imaging and behavioral assessments to investigate the effect of citalopram on restricted repetitive behaviors in people with autism spectrum disorders.
Condition | Intervention |
---|---|
Autism Spectrum Disorders |
Drug: Citalopram Drug: Placebo |
Study Type: | Interventional |
Study Design: | Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment |
Official Title: | Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders |
Estimated Enrollment: | 40 |
Study Start Date: | January 2007 |
Estimated Study Completion Date: | June 2013 |
Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active: Experimental
Individuals with an Autism Spectrum Disorder receiving citalopram
|
Drug: Citalopram
Pill, 5-20mg once a day for twelve weeks
|
Placebo: Placebo Comparator
Individuals with an Autistic Spectrum Disorder receiving placebo
|
Drug: Placebo
Placebo pill once a day for twelve weeks
|
Ages Eligible for Study: | 10 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Gabriel Dichter, PhD | 919-681-3169 | dichter@biac.duke.edu |
United States, North Carolina | |
UNC-Chapel Hill | Recruiting |
Chapel Hill, North Carolina, United States, 27759 |
Principal Investigator: | Gabriel S Dichter, PhD | The University of North Carolina, Chapel Hill |
Responsible Party: | University of North Carolina at Chapel Hill ( Gabriel Dichter/Principal Investigator ) |
Study ID Numbers: | 04-0975, NIH/NCRR K12 RR023248, The Dana Foundation |
Study First Received: | January 24, 2008 |
Last Updated: | February 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00609531 |
Health Authority: | United States: Institutional Review Board |
Restricted repetitive behaviors restricted interests Aspergers Autism |
Developmental Disabilities Child Development Disorders, Pervasive Mental Disorders Autistic Disorder |
Mental Disorders Diagnosed in Childhood Dexetimide Citalopram Serotonin |
Parasympatholytics Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Physiological Effects of Drugs Psychotropic Drugs Antiparkinson Agents Cholinergic Agents |
Serotonin Uptake Inhibitors Pharmacologic Actions Muscarinic Antagonists Pathologic Processes Serotonin Agents Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |